Switching antidepressants for treatment-resistant major depression
- PMID: 11575730
Switching antidepressants for treatment-resistant major depression
Abstract
A substantial proportion of patients suffering from major depression experience insufficient clinical response, despite appropriate treatment. Switching to a different monotherapy antidepressant medication is the preferred option for many patients and clinicians. The possible advantages of switching to a different monotherapy, as compared with adding a second agent (i.e., augmenting or combining), include reduced medication costs, fewer drug interactions, better adherence, and less patient burden over time. Response rates for switching, are based largely on open trials, which reveal a response rate of approximately 50%. These response rates are comparable to the response rates reported with augmentation or combination, again established largely by noncomparative open trials. This review article summarizes clinical considerations and available evidence regarding switching antidepressants in the treatment of major depression. Practical issues, such as when to consider switching and how to switch from one medication to another, are addressed.
Similar articles
-
Augmentation and combination strategies in treatment-resistant depression.J Clin Psychiatry. 2001;62 Suppl 18:4-11. J Clin Psychiatry. 2001. PMID: 11575733 Review.
-
Combining antidepressants for treatment-resistant depression: a review.J Clin Psychiatry. 2002 Aug;63(8):685-93. doi: 10.4088/jcp.v63n0805. J Clin Psychiatry. 2002. PMID: 12197448 Review.
-
Pharmacological strategies in treatment-resistant depression.West Afr J Med. 2003 Sep;22(3):211-8. doi: 10.4314/wajm.v22i3.27952. West Afr J Med. 2003. PMID: 14696943 Review.
-
Treatment of antidepressant nonresponders: augmentation or switch?J Clin Psychiatry. 1998;59 Suppl 15:35-41. J Clin Psychiatry. 1998. PMID: 9786309 Review.
-
Management of nonresponse and intolerance: switching strategies.J Clin Psychiatry. 2000;61 Suppl 2:10-2. J Clin Psychiatry. 2000. PMID: 10714618 Review.
Cited by
-
Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors.Health Psychol Res. 2022 Nov 3;10(4):39576. doi: 10.52965/001c.39576. eCollection 2022. Health Psychol Res. 2022. PMID: 36425231 Free PMC article.
-
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.Focus (Am Psychiatr Publ). 2021 Jun;19(2):145-160. doi: 10.1176/appi.focus.20200048. Epub 2021 Jun 17. Focus (Am Psychiatr Publ). 2021. PMID: 34690578 Free PMC article.
-
Cut points on the Patient Health Questionnaire (PHQ-9) that predict response to cognitive-behavioral treatments for depression.Gen Hosp Psychiatry. 2015 Sep-Oct;37(5):470-5. doi: 10.1016/j.genhosppsych.2015.05.009. Epub 2015 May 29. Gen Hosp Psychiatry. 2015. PMID: 26077754 Free PMC article.
-
Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?Am J Epidemiol. 2012 May 15;175(10):988-97. doi: 10.1093/aje/kwr394. Epub 2012 Mar 22. Am J Epidemiol. 2012. PMID: 22442287 Free PMC article.
-
The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.P T. 2008 Apr;33(4):212-46. P T. 2008. PMID: 19750165 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical